$44.270
-1.102 (-2.49%)收盘时
IONS 资讯
IONS 事件
Meta Shares Slide, Tesla Faces Investment Pressure
The major averages were broadly lower near noon amid renewed concerns over AI spending and an increase in oil prices. Meta shares are sliding despite strong revenue growth as investors weigh rising AI spending and legal costs, while Tesla is under pressure as its investment plans raise questions about returns.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Metareported mixed Q3 results, narrowed its FY26 capital expenditure guidance, and announced the establishment of a new Class C common stockTeslareported better-than-expected Q3 earnings, with CEO Elon Musk saying it will take at least a year to get Optimus robot production to 20,000 units per weekIBMreported upbeat Q3 results, with the company saying it is executing "solidly" against its prioritiesTexas Instrumentsreported better-than-expected Q3 results and provided upbeat Q4 earnings guidanceLockheed Martinprovided a "beat and raise" report for Q3 and announced a framework agreement with the Department of War for F-35 Lightning II fighter jets2. WALL STREET CALLS:BMO upgraded Blockto Outperform on Square volume accelerationNetflixdowngraded to Peer Perform at Wolfe ResearchCLSA and BNP Paribas upgraded Teslato Hold on potential SpaceXmergerRBC downgraded Dutch Broson competition, tough comparisonsBMO upgraded Ionisahead of Q3 report3. AROUND THE WEB:Infineum, a U.K.-based chemicals joint venture owned by Shelland ExxonMobil, has selected Bank of America to run a sale of the business, FT saysTSMCis looking into alternatives to rare-earth components in factory equipment, hoping to reduce the potential for Beijing export controls to disrupt plant operations, Reuters reportsDayOne Data Centers is weighing options for its U.S. IPO, including a potential delay or size cut, as volatility around data centers increases, Bloomberg saysSamsungand SK Hynixare upgrading their factories in China to produce more advanced memory chips, Reuters reportsSoutheastern Asset Management, an activist investor and big Mattelshareholder, has been considering whether to nominate new directors as part of a proxy fight and push the company toward a sale, Semafor says4. MOVERS:Biohavengains after the FDA accepted its new drug application resubmission for VyglxiaSpotifyincreases in New York after reporting Q3 results and providing guidance for Q4Kohl'shigher after Gordon Haskett upgraded the stock to BuyTTM Technologieslower after reporting Q3 results and providing guidance for Q4, FY26, and FY27Hexcelfalls after reporting Q3 results and increasing its buyback program to $750M5. EARNINGS/GUIDANCE:Honeywell Technologiesreported Q3 results and raised its guidance for Q4 and FY26Cencoraprovided guidance for FY26Badger Meterreported Q3 results, with EPS beating consensusFirstServicereported Q3 results, with CEO Scott Patterson noting he was "pleased" with the resultsPool Corp.reported Q3 results and backed its guidance for FY26INDEXES:Near midday, the Dow was down 211.23, or 0.40%, to 52,644.86, the Nasdaq was down 604.82, or 2.26%, to 26,098.04, and the S&P 500 was down 102.23, or 1.32%, to 7,654.94.
GSK Receives FDA Approval for Hibsago to Treat Chronic Hepatitis B
Ionis Pharmaceuticals (IONS) partner GSK (GSK) announced that the FDA has approved Hibsago for the treatment of chronic hepatitis B, or CHB, virus infection in combination with nucleoside analogue reverse transcriptase inhibitor therapy in adult patients without cirrhosis, receiving NrtI therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid, and with hepatitis B virus surface antigen levels =of 000 IU/ml, as determined by an FDA-authorized test. GSK licensed bepirovirsen from Ionis and collaborated with them on its development.
Ionis Pharmaceuticals Receives Positive EU Opinion for Tryngolza in Severe Hypertriglyceridemia
Ionis Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the indication extension for tryngolza as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridemia. If confirmed by the European Commission, tryngolza would be the first and only RNA-targeted therapy authorized in the EU for adults with sHTG and triglyceride levels greater than or equal to880 mg/dL. The positive CHMP opinion comes ahead of the previously anticipated timeline, with a final EC decision expected in the fourth quarter of 2026.
Genentech Reports Positive Interim Results in IgA Nephropathy Study
Genentech, a member of the Roche Group, announced positive prespecified interim results from the ongoing Phase III Imagination study evaluating investigational sefaxersen in adults with primary IgA nephropathy. The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio. Proteinuria is a key indicator of kidney damage and a reduction in UPCR is strongly associated with the preservation of long-term kidney function. Sefaxersen is a once-monthly subcutaneous injection designed to enable self-administration for people with IgAN. The safety and tolerability profile of sefaxersen was consistent with previously reported data, with no new safety signals identified. The Imagination study will continue as a blinded study to evaluate the change in kidney function over two years, as measured by estimated glomerular filtration rate at week 105. Interim analysis data will be presented at an upcoming medical congress and shared with health authorities, with the goal of bringing this treatment to patients as soon as possible.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。